Curis Lifesciences Ratios

Curis Lifesciences Ltd Ratios

The Curis Lifesciences Ltd Ratios page provides a complete fundamental analysis of Curis Lifesciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Curis Lifesciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Curis Lifesciences Ltd (NSE: CURIS, BSE: 94348) is currently trading at ₹99.90, with a market capitalization of ₹743.77M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Curis Lifesciences Ltd remains a key stock for fundamental analysis using Curis Lifesciences Ltd Ratios.

Curis Lifesciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Curis Lifesciences Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Curis Lifesciences Ltd Ratios.

Historically, the Curis Lifesciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

The decline in Curis Lifesciences Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Curis Lifesciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Curis Lifesciences Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Curis Lifesciences Ltd P/S ratio currently stands at 0, an important part of Curis Lifesciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

A stable or declining Curis Lifesciences Ltd P/S ratio indicates cautious market sentiment.

Curis Lifesciences Ltd Price to Cash Flow Ratio (P/CF)

The Curis Lifesciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Curis Lifesciences Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

The declining Curis Lifesciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Curis Lifesciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Curis Lifesciences Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Curis Lifesciences Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Curis Lifesciences Ltd EV/EBITDA ratio is currently 0, a key metric in Curis Lifesciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Curis Lifesciences Ltd EV/EBITDA indicates balanced valuation.

Curis Lifesciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Curis Lifesciences Ltd D/E ratio is currently 0.95, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.95
• 2023: 2.82
• 2022: 50.21
• 2021: 0

Curis Lifesciences Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Curis Lifesciences Ltd ROE currently stands at 55.92%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 55.92
• 2023: 174.48
• 2022: 0
• 2021: 0

Curis Lifesciences Ltd demonstrates strong profitability and efficient capital utilization.

Curis Lifesciences Ltd Ratios Analysis Summary

The Curis Lifesciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Curis Lifesciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Curis Lifesciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.